Around 30 centres and hospitals in Catalonia are studying promising treatments of COVID-19
The “Corporación Catalana de Medios Audiovisuales” has published a report on the RiPCoN project, in which IRB Barcelona’s Structural Bioinformatics and Network Biology is participating. Headed by Patrick Aloy, this lab is conducting a computational study of the interactions between the coronavirus and human cells with the aim to identify drugs already on the market or under development that can tackle the spread of the virus. The goal is to identify an antiviral treatment and, in the long-term, a possible vaccine.
In addition, various media have reported on the efforts made by IRB Barcelona to conduct mass screening for the disease.
Link to: CCMA
Link to: CCMA
Link to: La Vanguardia
Link to: ABC
Related content
News
Several media have reported on the platform set up by IRB Barcelona, the Center for Genomic Regulation (CRG) and the Institute for Bioengineering of Catalonia (IBEC) for mass testing for COVID-19, which seeks to contribute to halting the spread of the virus. In this regard, the labs at IRB Barcelona will conduct sample analysis to detect infected individuals during lockdown and also when confinement measures are progressively relaxed.
The Centre for Genomic Regulation (CRG) is coordinating a task force with the Institute for Research in Biomedicine (IRB Barcelona) and the Institute for Bioengineering of Catalonia (IBEC), as requested by Generalitat de Catalunya, to set up mass testing for citizens to stop the spread of the new coronavirus outbreak.
Several media have reported on the collaboration between IRB Barcelona and Amazon. In this regard, IRB Barcelona’s Structural Bioinformatics and Network Biology Laboratory, headed by ICREA researcher Patrick Aloy, is collaborating with the American giant in the development of a tool based on Chemical Checker technology. This new tool aims to rapidly process the large volume of articles on COVID-19 and extract results that could be relevant in the search for a treatment.
